Population pharmacokinetic/pharmacodynamic modeling of cetrorelix, a novel LH-RH antagonist, and testosterone in rats and dogs

Pharmaceutical Research

Volumn 17, Issue 3, 2000, Pages 328-335

  Schwahn, Martin ^a   Nagaraja, Nelamangala V ^b   Derendorf, Hartmut ^b  

^a ASTA MEDICA AG   (Germany)

^b UNIVERSITY OF FLORIDA HEALTH   (United States)

Author keywords

Cetrorelix; Dog; Luteinising hormone releasing hormone (LH RH) antagonist; Pharmacokinetics; Population PK PD modeling; Rat; Testosterone

Indexed keywords

CETRORELIX; TESTOSTERONE;

ANIMAL EXPERIMENT; AREA UNDER THE CURVE; ARTICLE; DOG; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG HALF LIFE; ENZYME IMMUNOASSAY; FEMALE; MALE; NONHUMAN; POPULATION MODEL; PRIORITY JOURNAL; RADIOIMMUNOASSAY; RAT; TESTOSTERONE SYNTHESIS;

ANIMALS; DOGS; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; GONADAL STEROID HORMONES; GONADOTROPIN-RELEASING HORMONE; HORMONE ANTAGONISTS; MALE; MODELS, BIOLOGICAL; RATS; RATS, WISTAR; TESTOSTERONE;

EID: 0034005062     PISSN: 07248741     EISSN: None     Source Type: Journal    
DOI: 10.1023/A:1007557207590     Document Type: Article

References (30)

1. 1. E. Knobil. The neuroendocrine control of the menstrual cycle. Recent Prog. Horm. Res., 36:53-80 (1980).
2. 2. S. Fukuda. Circadian rhythm of serum testosterone levels in male beagle dogs - effects of lightning time zone. Exp. Anim., 39(1):65-68 (1990).
3. 3. L. R. DePalatis, J. Moore, and R. E. Falvo. Plasma concentrations of testosterone and LH in the male dog. J. Reprod. Fert., 52: 201-207 (1978).
4. 4. S. Bajusz, M Kovacs, M. Gazdag, L. Bokser, T. Karashima, V. J. Csernus, T. Janaky, J. Guoth, and A. V. Schally. Highly potent antagonists of luteinizing hormone-releasing hormone free of edematogenic effects. Proc. Natl Acad. Sci. USA 85:1637-1641 (1988).
5. 5. M. Schwahn, P. Romeis, G. Peter, H. Derendorf, and M. Herbst. Absolute bioavailability and dose proportionality of CET, a novel LH-RH antagonist, in male and female rats. Arch. Pharmacol. 355 (4):R8 (1997).
6. 6. H. Berger, N. Heinrich, H. Schäfer, I. Baeger, and B. Mehlis. Gonadotropin-releasing hormone (GnRH) pharmacokinetics: peptide hormone pharmacokinetics needs clarification. Life Sci. 42:985-991 (1988).
7. 7. N. I. Chu, R. L. Chan, K. M. Hama, and M. D. Chaplin. Disposition of Narfarelin acetate, a potent luteinizing hormone-releasing hormone agonist, in rats and rhesus monkeys. Drug Metab. Dispos. 13:560-565 (1985).
8. 8. H. Berger, N. Heinrich, E. Albrecht, U. Kertscher, J. Oehlke, M. Bienert, H. Schäfer, I. Baeger, and B. Mehlis. Gonadotropin-releasing hormone (GnRH) analogs: relationship between their structure, proteolytic inactivation and pharmacokinetics in rats. Regul. Pept. 33:299-311 (1991).
9. 6]-luteinizing hormone releasing hormone: its application to animal pharmacokinetic studies after single injection and long-acting formulation administration. Regul. Pept. 14:155-167 (1986).
10. 10. H. Okada, Y. Inoue, T. Heya, H. Ueno, Y. Ogawa, and H. Touchi. Pharmacokinetics of once-a-month injectable microspheres of leuprolide acetate. Pharm. Res. 8:787-791 (1991).
11. 11. E. Hudon, J. J. Rondeau, V. Lenaerts, P. Wüthrich, F. Boutignon, R. Deghenghi, S. Marleau, N. Yamagutchi, A. Adam, and H. Ong. Radioimmunoassay of meterelin and pharmacokinetics after single injection and implant administration in dogs. J. Pharm. Sci. 86:172-178 (1997).
12. 12. F. Haviv, E. N. Bush, J. Knittle, and J. Greer. LHRH Antagonists. In Borchard (eds), Integration of pharmaceutical discovery and development, Plenum Press, New York, 1998.
13. 13. S. Sorensen, J. J. Rondeau, V. Lenaerts, F. Boutignon, P. Wüthrich, R. Deghenghi, A. Adam, and H. Ong. Radioimmunoassay of antarelix, a luteinising hormone releasing-hormone antagonist, in plasma and its application for pharmacokinetic study in dogs. J. Immunoassay 17:205-226 (1996).
14. 14. R. L. Chan, W. Ho, A. S. Webb, J. A. LaFargue, and C. A. Nerenberg. Disposition of detirelix, a potent luteinising hormone-releasing hormone antagonist, in rats and monkeys. Pharm. Res. 5:335-340 (1988).
15. 15. R. L. Chan, S. C. Hsieh, P. E. Haroldsen, W. Ho, and J. J. Nestor, Jr. Disposition of RS-26306, a potent luteinizing hormone-releasing hormone antagonist, in monkeys and rats after single intravenous and subcutaneous administration. Drug Metab. Dispos. 19:858-864 (1991).
16. 16. V. J. Csernus, B. Szende, K. Groot, T. W. Redding, and A. V. Schally. Development of radioimmunoassay for a potent luteinizing hormone-releasing hormone antagonist. Drug Res. 40: 111-118 (1990).
17. 17. H. H. Raffel, M. Locher, H. O. Borbe. High-performance liquid chromatographic assay for the determination of the decapeptide cetrorelix, a novel luteinizing hormone-releasing hormone antagonist, in human plasma. J Chromatography B. 653:102-105 (1994).
18. nd Ed. Marcel Dekker Inc., 1982, pp. 155-161.
19. 19. N. L. Dayneka, V. Garg, and W. J. Jusko. Comparison of four basic models of indirect pharmacodynamic responses. J. Pharmacokin Biopharm. 21:457-478 (1993).
20. 20. F. Mentre and R. Gomeni. A two step iterative algorithm for estimation in nonlinear mixed-effect models with an evaluation in population pharmacokinetics. J. Biopharm. Stat. 5:141-158 (1995).
21. 21. User Manual, P-Pharm, (Ver. 1.5), Innaphase, Champs sur Marne, France (1994).
22. 22. A. Bartke, R. E. Steele, N. Musto, and B. V. Caldwell. Fluctuations in plasma testosterone levels in adult male rats and mice. Endocrinol. 92:1223-1228 (1973).
23. 23. A. R. Günzel-Apel, H. G. Brinckmann, and H. O. Hoppen. Dynamics of LH and testosterone secretion in male beagles of different age. Reprod. Dom. Anim. 25:78-86 (1990).
24. 24. J-M. Gries, A. Munafo, H. C. Porchet, and D. Verotta. Down-regulation models and modeling of testosterone production induced by recombinant human choriogonadotropin. J. Pharmacol. Exp. Ther. 289:371-377 (1999).
25. 25. G. Halmos, A. V. Schally, J. Pinski, M. Vadillo-Buenfil, and K. Groot. Down-regulation of pituitary receptors for luteinizing hormone-releasing hormone (LH-RH) in rats by LH-RH antagonist Cetrorelix. Proc. Natl. Acad. Sci. USA 93:2398-2402 (1996).
26. 26. K. E. Fattinger, D. Verotta, H. C. Porchet, A. Munafo, J-Y. Le Cotonnec, and L. B. Sheiner. Modeling a bivariate control system: LH and testosterone response to the GnRH antagonist antide. Am. J. Physiol. 271:E775-E787 (1996).
27. 27. A. Lasdun, S. Reznik, C. J. Molineaux, and M. Orlowski. Inhibition of endopeptidase 24.15 slows the in vivo degradation of luteinizing hormone-releasing hormone. J. Pharmacol. Exp. Ther. 251:439-447 (1989).
28. 28. B. Horsthemke, H. Knisatschek, J. Rivier, J. Sandow, and K. Bauer. Degradation of luteinizing hormone-releasing hormone and analogs by adeno-hypophyseal peptidases. Biochem. Biophys. Res. Commun. 100:753-759 (1981).
29. 29. K. Hakola, D. Pierroz, A. Aebi, B. A. M. Vuagnat, M. L. Aubert, and I. Huhtaniemi. Dose and time relationship of intravenously injected rat recombinant luteinizing hormone and testicular testosterone secretion in the male rat. Biol. Reproduction 59:338-343 (1998).
30. 30. B. W. Knol, S. J. Dielemann, M. M. Bevers, and W. E. van den Brom. GnRH in the male dog: dose-response relationship with LH and testosterone. J. Reprod. Fert. 98:159-161 (1993).